Board, committees and an organigram. How we are organized and who does what: learn more about us.
Oncode Institute operates with a small team to provide valorization services, general management and support to all the Oncode Researchers across the Partner Institutions. Oncode does not have its own research facilities or staff. Every Oncode Researcher is employed by one of the Partner Institutions, at which the actual research is conducted.
Oncode’s staff is guided and supported by its board and committees. The Oncode team and the members of the boards and committees perform their duties in awareness of their extraordinary responsibility to spend public monies in the most effective and efficient manner possible, to serve society and to set an example.
Oncode is founded on the assumption that everyone involved in the Institute is committed to constantly improving Oncode and its way of working. Oncode listens. Not only to its boards, committees and the Oncode team, but to all Oncode Researchers, partners and patients. Because all of us together know more than the few managing the Institute. If you have any questions or suggestions, please feel free to contact us at any time.
The members of the Managing Board operate and manage Oncode, taking into account that Oncode has an important social responsibility. The Managing Board consists of a General Director, Valorization Director and a Chief Scientific Officer.
Ton Rijnders has extensive experience in leading multidisciplinary organizations with individual experts and leading a portfolio of collaborations with public and private partners.
"Innovative cancer treatments can be realized only through a combination of individual excellence and collaborative development."
Angus Livingstone has played critical roles in the creation of many Canadian technology transfer and commercialisation initiatives. The enormous valorization potential grounded in The Netherlands’ excellent fundamental cancer research led him to cross the ocean to become Oncode’s Valorization Director.
"I am excited to bring to the Netherlands my 30 years of experience in translating academic research into social and economic benefits."
Oncode Investigator Geert Kops is Scientific Director and chair of the Research Management Committee of Oncode Institute. Geert Kops is group leader at the Hubrecht Institute and professor of Molecular Tumor Cell Biology at the University Medical Center Utrecht. His group studies the signaling networks that regulate chromosome segregation, the evolution of cell division processes and the role of chromosomal instability in cancer.
"Synergy between Oncode researchers will create even more breakthrough discoveries, also towards the clinic.”
Eduard Klasen has served in many leaderships roles during his extensive career. After ten years as member of the Executive Board of Leiden University Medical Center, he currently is an advisor to the Board. In 2012 he was knighted by Her Majesty the Queen of the Netherlands. Eduard is member of the Supervisory Board of VU, Free University Amsterdam, chairman of the Supervisory Board of the Wilhelmina Hospital Assen, chairman of the Supervisory Board of NIVEL, advisor to the UMCG, University Medical Center Groningen, among various other supervisory positions.
Ben Feringa is Jacobus van ‘t Hoff Distinguished Professor of Molecular Sciences at the University of Groningen. His research interest includes stereochemistry, organic synthesis, asymmetric catalysis, molecular switches and motors, self-assembly, molecular nanosystems and photopharmacology. He received the 2016 Nobel Prize in chemistry and was knighted by Her Majesty the Queen of the Netherlands in 2008. He is Board Member of the Royal Netherlands Academy of Sciences (KNAW), Chairman Board Chemistry Division of the Netherlands Science Foundation NWOCW among many other involvements.
Until 2017, Edvard Beem has served as co-director of The Netherlands Organisation for Health Research and Development (ZonMw). Since its establishment in 2001, he was responsible for research strategy, public-private co-operation and international relations at ZonMw. Edvard was originally trained as a biochemist and spend most of his scientific career at the Netherlands Cancer Institute. He also serves as the chair of the General Assembly of Joint Programming Initiative “More Years, Better Lives” and held governmental positions in numerous international funding consortia promoting European and global collaboration in research, innovation and infrastructures.
Erica van Wuijtswinkel
Erica van Wuijtswinkel is the patient representative within the Oncode Supervisory Board. She is also a member of the patient advisory board at the Dutch Cancer Society (KWF). In her professional career she has dealt with navigating through subsidy opportunities in several different projects. Here Erica has also learned to take a holistic and multi-stakeholder approach to projects and to see the bigger picture as opposed to focusing on one side of the coin only. During her career she developed a talent for implementing policy, promoting cooperation within and between organizations and combining technology, support & care.
Johan van de Gronden
Johan van de Gronden is executive director of the Dutch Cancer Society. His career spans senior management and leadership roles across civil society, government and business. He was the CEO of the World Wide Fund for Nature (WWF) in the Netherlands for a decade, served the international community at the United Nations Development Programme (UNDP) and the Dutch Foreign Office. He now chairs the boards of the International Union for Conservation of Nature (IUCN), the Early Music Foundation and the Amazon Conservation Team in Brussels.
Paul Smits is the Dean and vice-president of the board of directors of the Radboud University Medical Centre in Nijmegen. After a training in internal medicine and gaining international experience at Harvard Medical School, he became professor of pharmacology in 1995 Radboud University. Between 2008 and 2012, Paul has served as scientific director of the Nijmegen Centre for Evidence Based Practice (NCEBP), was a member of the Dutch Medicines Evaluation Board and the Standing Committee on Health Care at the Health Council of the Netherlands.
René Kuijten is one of the initiators of Oncode Institute and is managing partner at the international healthcare investment firm Life Sciences Partners (LSP). After his training as a physician in Utrecht he obtained a PhD degree as a WHO fellow, based on cancer research performed at the University of Pennsylvania. He received his MBA from INSEAD and was a consultant at McKinsey & Co. in Amsterdam, Zurich and Brussels from 1992-2000, a.o. leading their healthcare practice. In 2001 he joined LSP and has founded and supported many life science companies. René also serves as a member of the steering committee in the Dutch Topsector Life Science & Health and is in the management board of the Dutch private equity and venture capital association (NVP).
To ensure good governance, Oncode has developed its Good Governance Charter based on the rules in the Dutch Corporate Governance Code and the Good Governance Code for charities (SBF-Code Goed Bestuur).
The Good Governance Charter constitutes the regulations of Oncode’s most prominent and influential boards and committees, and also comprehends key policies. Please find the Good Governance Charter here. Please note that the Good Governance Charter is still work in progress and will be finalized soon.
Oncode Institute is a foundation. Please find Oncode’s articles of association here.